Four Goldman Sachs stock picks make sense for growth and income investors charting a course for the rest of what could be a ...

Pfizer offers a 6.7% dividend yield, trading at a low valuation with resilient drug portfolio growth. Realty Income Corp. has ...

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...

These areas include cardiovascular, infectious diseases, and oncology, with notable brands like Comirnaty, Paxlovid, and Eliquis ... Consumer Banking & Lending, Commercial Banking, Corporate ...

It operates across multiple industry segments, including consumer and commercial banking ... including the anticoagulant Eliquis, which saw an 11% year-over-year sales increase, reaching $3 ...

SOTIC2’s commercial performance was lower than expected ... that we think has the potential to offer efficacy on a par with Eliquis, but with an improved bleeding profile. And we’re looking ...

has unlawfully denied its plan to pay rebates to qualifying organisations who source Eliquis only after they have bought the drug at normal commercial prices. In court documents, BMS' counsel ...

Commercial Launch Preparation ... the tail is longer and you see this for instance classically with drugs like Eliquis that Andrew co led as he was then at Pfizer or Entresto if you look at ...

BMS is a longstanding player in cardiovascular with drugs like Pfizer-partnered Eliquis (apixaban ... because the biotech was reluctant to extend commercial rights covered by the deal.